Protecting the blood supply from emerging pathogens: The role of pathogen inactivation

Transfusion Clinique et Biologique

Volumn 16, Issue 2, 2009, Pages 70-74

  Blajchman, M A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Blood cellular products; Blood products; Nanofiltration; Pathogen inactivation; Photosensitive chemicals; Plasma; Solvent d tergent

Indexed keywords

ALKYLATING AGENT; AMOTOSALEN; NONOXINOL 9; PHOTOSENSITIZING AGENT; PLASMA PROTEIN; RIBOFLAVIN;

BACTERIUM; BLOOD COMPONENT; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG INDUSTRY; ERYTHROCYTE; HEMATOLOGICAL PROCEDURES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERVOLEMIA; MORTALITY; NANOFILTRATION; PATHOGEN INACTIVATION; PATHOGENESIS; PROTOZOON; SHORT SURVEY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS INACTIVATION; VIRUS TRANSMISSION;

BLOOD PLATELETS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASES, EMERGING; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; INFECTION; PHOTOSENSITIZING AGENTS; VIRUS DISEASES;

EID: 67349133489     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2009.04.004     Document Type: Short Survey

References (20)

1. Alter H.J., and Klein H.G. The hazards of blood transfusion in historical perspective. Blood 112 (2008) 2617-2626
2. Hendrickson J.E., and Hillyer C.D. Noninfectious serious hazards of transfusion. Anesth Analg 108 (2009) 759-769
3. Vamvakas E.C., and Blajchman M.A. Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 113 (2009) 3406-3417
4. Alter H.J. Pathogen reduction: A precautionary principle paradigm. Transfus Med Rev 22 (2008) 97-102
5. Bryant B.J., and Klein H.G. Pathogen inactivation: The definitive safeguard for the blood supply. Arch Pathol Lab Med 131 (2007) 719-733
6. Klein G.H., Anderson D., Bernardi M.J., Cable R., Carey W., Hoch J.S., et al. Pathogen inactivation: Making decisions about new technologies. Report of a consensus conference. Transfusion 47 (2007) 2338-2347
7. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: Pathogen inactivation-making decisions about new technologies. Transfus Med Rev 22 (2008) 1-34
8. Goldman M., and Blajchman M.A. Blood product-associated bacterial sepsis. Transfus Med Rev 5 (1991) 73-83
9. Blajchman M.A., Goldman M., and Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 18 (2004) 11-24
10. Yomtovian R.A., Palavecino E.L., Dysktra A.H., Downes K.A., Morrissey A.M., Bajaksouzian S., et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 46 (2006) 719-730
11. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfus Med Rev 19 (2005) 110-126
12. Kleinman S., Dumont L.J., Tomasulo P., Bianco C., Katz L., Benjamin R.J., et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: An illustration of the need for proper risk assessments. Transfusion 49 5 (2009) 903-912
13. Blajchman M.A., and Vamvakas E.C. The continuing risk of transfusion-transmitted infections. N Engl J Med 355 (2006) 1303-1305
14. Burnouf T. Modern plasma fractionation. Transfus Med Rev 21 (2007) 101-117
15. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 23 (2009) 124-133
16. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 104 (2004) 1534-1541
17. Goodrich R.P., Edrich R.A., Li J., and Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci 35 (2006) 5-17
18. Goodrich R.P., Murthy K.K., Doane S.K., Fitzpatrick C.N., Morrow L.S., Arndt P.A., et al. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 49 (2009) 64-74
19. Reddy H.L., Dayan A.D., Cavagnaro J., Gad S., Li J., and Goodrich R.P. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 22 (2008) 133-153
20. Klein HG, Glynn SA, Ness PM, Blajchman MA. Research opportunities for pathogen reduction/inactivation of blood components: Summary of an NHLBI workshop. Transfusion, in press. doi: 10.1111/j.1537-2995.2009.02210.x.